About apogee therapeutics inc - APGE
Apogee Therapeutics, Inc. is a clinical stage biotechnology company. It offers treatment of atopic dermatitis (AD), ashma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded by Andrew Gottesdiener and Nimish P. Shah in 2022 and is headquartered in Waltham, MA.
APGE At a Glance
Apogee Therapeutics, Inc.
221 Crescent Street
Waltham, Massachusetts 02453
| Phone | 1-650-394-5230 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -255,843,000.00 | |
| Sector | Health Technology | Employees | 261 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
APGE Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 5.712 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -13.582 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.002 |
APGE Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -980,241.379 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
APGE Liquidity
| Current Ratio | 26.566 |
| Quick Ratio | 26.566 |
| Cash Ratio | 26.166 |
APGE Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -30.258 |
| Return on Equity | -31.572 |
| Return on Total Capital | -28.03 |
| Return on Invested Capital | -31.303 |
APGE Capital Structure
| Total Debt to Total Equity | 0.979 |
| Total Debt to Total Capital | 0.97 |
| Total Debt to Total Assets | 0.944 |
| Long-Term Debt to Equity | 0.591 |
| Long-Term Debt to Total Capital | 0.586 |